← Leaderboards
Martin Beinborn
Velum, Inc.
$2,057,695
Attributed
$4,115,389
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,115,389 · 3
By mechanism
R42$3,800,047 · 2
R41$315,342 · 1
Top collaborators
- Krishna Kumar6 shared
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsPhysiologicalObesity EpidemicPeptidesPhase 1 StudyPhase 2 StudyHormonesObesityPathway InteractionsEngineeringIn VivoAgonistGlucagon-Like Peptide 1InjectionsDiabetes MellitusHalf-LifeNon-Insulin-Dependent Diabetes MellitusN-TerminalBody Weight DecreasedObesity TreatmentAnimal ModelClinicAnimalsPrototype
Grant awards (6)
A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome$959,031
R42 · FY2025 · DK
Peptide YY triagonist weight loss drugs$315,342
R41 · FY2025 · DK
A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome$1,135,509
R42 · FY2024 · DK
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1$478,280
R42 · FY2023 · AG
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1$738,741
R42 · FY2022 · AG
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1$488,486
R42 · FY2021 · AG